Tocilizumab modulates serum levels of adiponectin and chemerin in patients with rheumatoid arthritis: potential cardiovascular protective role of IL-6 inhibition

Rheumatoid Arthritis

IL-6 is an independent predictive factor of drug survival after dose escalation of infliximab in patients with rheumatoid arthritis

Mod Rheumatol.

Takasugi K, Nishida K, Natsumeda M, Yamashita M, Yamamoto W, Ezawa K

doi: 10.1080/14397595.

Rheumatoid Arthritis

Dickkopf-1 (Dkk-1) serum levels in systemic sclerosis and rheumatoid arthritis patients: correlation with the Trabecular Bone Score (TBS)

Clin Rheumatol.

Ruaro B, Casabella A, Paolino S, Pizzorni C, Ghio M, Seriolo C, Molfetta L, Odetti P, Smith V, Cutolo M

doi: 10.1007/s10067-

Rheumatoid Arthritis

Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab

Ann Rheum Dis.

Shafran IH, Alasti F, Smolen JS, Aletaha D

doi: 10.1136/annrheumdis-2019-215987.

Rheumatoid Arthritis

Prevalence of depression and anxiety in rheumatoid arthritis patients and their associations with serum vitamin D level

Clin Rheumatol.

Pu D, Luo J, Wang Y, Ju B, Lv X, Fan P, He L

doi: 10.1007/s10067-017-3874-4.

Rheumatoid Arthritis

Differential effects of IL-6 blockade tocilizumab and TNF inhibitors on angiogenesis in synovial tissues from patients with rheumatoid arthritis.

Mod Rheumatol.

Hirohata S, Abe A, Murasawa A, Kanamono T, Tomita T, Yoshikawa H

Rheumatoid Arthritis

Connective tissue remodelling is differently modulated by tocilizumab versus methotrexate monotherapy in patients with early rheumatoid arthritis: the AMBITION study

Arthritis Res Ther

Drobinski PJ, Bay-Jensen AC, Karsdal MA, Sardar S, Siebuhr AS

doi: 10.1186/s13075-020-02378-7

Rheumatoid Arthritis

Tocilizumab improves the proatherothrombotic profile of rheumatoid arthritis patients modulating endothelial dysfunction, NETosis, and inflammation

Transl Res.

Ruiz-Limón P, Ortega R, Arias de la Rosa I, Abalos-Aguilera MDC, Perez-Sanchez C, Jimenez-Gomez Y, Peralbo-Santaella E, Font P, Ruiz-Vilches D, Ferrin G, Collantes-Estevez E, Escudero-Contreras A, López-Pedrera C, Barbarroja N

doi: 10.1016/j.trsl.2016.12.003.

Rheumatoid Arthritis

High Serum Interleukin-6 is Associated With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab from Adalimumab or Methotrexate in a Post Hoc Analysis

Arthritis Rheumatol.

Boyapati A, Schwartzman S, Msihid J, Choy E, Genovese MC, Burmester GR, Lam G, Kimura T, Sadeh J, Weinreich DM, Yancopoulos GD, Graham NMH

doi: 10.1002/art.41299.

Psoriatic Arthritis

Serum CRP, IL-17A, and IL-17F levels are responsive to ustekinumab in psoriatic arthritis: lessons from the PSUMMIT study programme

Arthritis Rheumatol.

Siebert S, Sweet K, Dasgupta B, Campbell K, McInnes IB, Loza MJ

doi: 10.1002/art.40921.

Related content

IL-6 is an independent predictive factor of drug survival after dose escalation of infliximab in patients with rheumatoid arthritis

Dickkopf-1 (Dkk-1) serum levels in systemic sclerosis and rheumatoid arthritis patients: correlation with the Trabecular Bone Score (TBS)

Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab

Prevalence of depression and anxiety in rheumatoid arthritis patients and their associations with serum vitamin D level

Differential effects of IL-6 blockade tocilizumab and TNF inhibitors on angiogenesis in synovial tissues from patients with rheumatoid arthritis.

Connective tissue remodelling is differently modulated by tocilizumab versus methotrexate monotherapy in patients with early rheumatoid arthritis: the AMBITION study

Tocilizumab improves the proatherothrombotic profile of rheumatoid arthritis patients modulating endothelial dysfunction, NETosis, and inflammation

High Serum Interleukin-6 is Associated With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab from Adalimumab or Methotrexate in a Post Hoc Analysis

Serum CRP, IL-17A, and IL-17F levels are responsive to ustekinumab in psoriatic arthritis: lessons from the PSUMMIT study programme